Product: Liptruzet (ezetimibe and atorvastin) tablets,10 mg/40 mg, a) 30 count blister    (NDC 66582-322-30), b) 90 count blister  (NDC 66582-322-54), Rx only, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc, Whitehouse Station, NJ 08889
Reason for recall: This recall of LIPTRUZET is being initiated due to  packaging defects. Some of the outer laminate foil pouches allowed in air and moisture, which could potentially decrease the effectiveness or change the characteristics of the product.
Recall initiated: 20140113
Status: Terminated
Classification: Class III
Recall type: Voluntary: Firm initiated